{ "run": { "id": "cmnr149jx04gep658uoroa2qz", "region": "US", "assetId": "cmnr149ip04gap658h8pfpjeg", "ticker": "IQV", "snapshotId": "cmnr149ix04gcp6586fbg8836", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:09.210Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr149ix04gcp6586fbg8836", "assetId": "cmnr149ip04gap658h8pfpjeg", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 172.54, "dayLow": 171.77, "volume": 1401957, "dayHigh": 178.565, "currency": "USD", "prevClose": 170.62, "week52Low": 134.65, "week52High": 247.05 }, "fundamentals": { "pe": 28.4968394437421, "beta": 1.11188787853301, "epsTTM": 7.91, "fcfTTM": 1512000000, "growth": { "epsYoy": 0.04491413474240421, "revenueYoy": 0.0587471600129828 }, "sector": "Services-Commercial Physical & Biological Research", "margins": { "net": 0.08338442673206621, "gross": 0.09779276517473942, "operating": 0.1337829552421827 }, "website": "http://iqvia.com", "industry": "Contract Research Organization", "pegRatio": 6.34473748791552, "ebitdaTTM": 3233000000, "forwardPe": 19.4991349480969, "marketCap": 26500000000, "totalCash": 1980000000, "totalDebt": 15724000000, "debtEquity": 2.41796094110411, "quickRatio": 0.6645478532022068, "revenueTTM": 16310000000, "companyName": "IQVIA HOLDINGS INC.", "priceToBook": 5.8443407239819, "currentRatio": 0.7494603022307508, "dividendYield": 0.0341437162438846, "returnOnAssets": 0.04541811381244991, "returnOnEquity": 0.209134245732739, "analystOpinions": null, "businessSummary": "IQVIA Holdings, Inc. is an American company based in Durham, North Carolina, focused on health information technology and clinical research. The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and …", "enterpriseValue": 52491979000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 93000, "sharesOutstanding": 169700000, "enterpriseToEbitda": 16.23630652644603, "analystTargetMedian": null, "enterpriseToRevenue": 3.21839233599019, "operatingCashflowTTM": 2654000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:09.177Z" }, "results": [ { "id": "cmnr149jz04ggp658znsazzdy", "runId": "cmnr149jx04gep658uoroa2qz", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"IQV\",\"currency\":\"USD\",\"current_price\":172.54,\"target_price_6m\":185,\"target_price_12m\":195,\"recommendation\":\"BUY\",\"confidence\":0.6,\"thesis_bullets\":[\"Leading CRO with differentiated data/analytics moat across healthcare\",\"Trading ~30% below 52-week high creates attractive entry point\",\"FCF yield of ~5.7% supports deleveraging and shareholder returns\",\"High leverage (debt/equity 2.42) constrains financial flexibility materially\",\"Revenue and EPS growth decelerating to mid-single digits tempers upside\"],\"key_drivers\":[{\"driver\":\"Pharma R&D spending trends driving CRO demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"AI and data analytics monetization across 1.2B patient records\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"High debt burden ($15.7B) limiting strategic flexibility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Backlog conversion providing multi-year revenue visibility\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion potential from 13.4% toward 15%+\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Growth deceleration (rev +5.9%, EPS +4.5% YoY)\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Current ratio below 1.0 signals near-term liquidity tightness\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend initiation signals cash return commitment\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Sustained pharma R&D budget cuts reduce new contract wins\",\"Rising interest rates increase debt servicing costs on $15.7B debt\",\"Regulatory changes or clinical trial delays compress margins\",\"Competition from other CROs (Fortrea, PPD, Syneos) pressures pricing\",\"Macro downturn triggers multiple compression on leveraged balance sheet\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.15,\"wacc\":0.095,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":145,\"prob\":0.25,\"notes\":\"Pharma spending cuts and deleveraging stall compress multiple to 14x EV/EBITDA.\"},\"base\":{\"target_price\":195,\"prob\":0.50,\"notes\":\"Steady 5-6% growth, margin improvement to 15%, modest re-rating to 17-18x EV/EBITDA.\"},\"bull\":{\"target_price\":230,\"prob\":0.25,\"notes\":\"AI/data monetization accelerates top-line to 8%+, multiple re-rates above 20x EV/EBITDA.\"}},\"method_notes\":\"Blended EV/EBITDA and forward PE approach. Base assumes NTM EPS ~$9.30 at ~21x PE and EV/EBITDA re-rating from 16.2x to ~17.5x as growth stabilizes. Probability-weighted scenario value ~$191 supports ~13% 12M upside, consistent with BUY. High leverage and decelerating growth limit confidence to moderate. Sell-side targets noted but not used as inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained pharma R&D budget cuts reduce new contract wins", "Rising interest rates increase debt servicing costs on $15.7B debt", "Regulatory changes or clinical trial delays compress margins", "Competition from other CROs (Fortrea, PPD, Syneos) pressures pricing", "Macro downturn triggers multiple compression on leveraged balance sheet" ], "ticker": "IQV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady 5-6% growth, margin improvement to 15%, modest re-rating to 17-18x EV/EBITDA.", "target_price": 195 }, "bear": { "prob": 0.25, "notes": "Pharma spending cuts and deleveraging stall compress multiple to 14x EV/EBITDA.", "target_price": 145 }, "bull": { "prob": 0.25, "notes": "AI/data monetization accelerates top-line to 8%+, multiple re-rates above 20x EV/EBITDA.", "target_price": 230 } }, "confidence": 0.6, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.055, "terminal_multiple": 18, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Pharma R&D spending trends driving CRO demand", "impact": "HIGH", "direction": "POS" }, { "driver": "AI and data analytics monetization across 1.2B patient records", "impact": "HIGH", "direction": "POS" }, { "driver": "High debt burden ($15.7B) limiting strategic flexibility", "impact": "HIGH", "direction": "NEG" }, { "driver": "Backlog conversion providing multi-year revenue visibility", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion potential from 13.4% toward 15%+", "impact": "MED", "direction": "POS" }, { "driver": "Growth deceleration (rev +5.9%, EPS +4.5% YoY)", "impact": "MED", "direction": "NEG" }, { "driver": "Current ratio below 1.0 signals near-term liquidity tightness", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend initiation signals cash return commitment", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended EV/EBITDA and forward PE approach. Base assumes NTM EPS ~$9.30 at ~21x PE and EV/EBITDA re-rating from 16.2x to ~17.5x as growth stabilizes. Probability-weighted scenario value ~$191 supports ~13% 12M upside, consistent with BUY. High leverage and decelerating growth limit confidence to moderate. Sell-side targets noted but not used as inputs. Not investment advice.", "current_price": 172.54, "recommendation": "BUY", "thesis_bullets": [ "Leading CRO with differentiated data/analytics moat across healthcare", "Trading ~30% below 52-week high creates attractive entry point", "FCF yield of ~5.7% supports deleveraging and shareholder returns", "High leverage (debt/equity 2.42) constrains financial flexibility materially", "Revenue and EPS growth decelerating to mid-single digits tempers upside" ], "target_price_6m": 185, "target_price_12m": 195 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 38586, "createdAt": "2026-04-09T05:21:09.210Z", "usage": { "inputTokens": 3694, "outputTokens": 1918, "costUsd": 0.06642 } }, { "id": "cmnr149jz04gjp6587341bl1h", "runId": "cmnr149jx04gep658uoroa2qz", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"IQV\",\n \"currency\": \"USD\",\n \"current_price\": 172.54,\n \"target_price_6m\": 174.0,\n \"target_price_12m\": 175.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\"Moderate revenue growth driven by healthcare digitization.\", \"Stable operating margins with potential efficiency gains.\", \"High debt levels pose financial risk.\", \"Industry competition may pressure pricing.\", \"Fair valuation at current multiples.\"],\n \"key_drivers\": [\n {\"driver\": \"Healthcare data demand\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Clinical trial outsourcing trend\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Debt servicing costs\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory changes in pharma\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Technological advancements in CRO\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Economic cycles affecting R&D spend\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"M&A activity in sector\", \"impact\": \"LOW\", \"direction\": \"POS\"}\n ],\n \"risks\": [\"High leverage increasing financial vulnerability.\", \"Intense competition from other CROs and tech firms.\", \"Regulatory uncertainties in healthcare data usage.\", \"Macroeconomic downturns reducing pharmaceutical R&D.\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.14,\n \"wacc\": 0.09,\n \"terminal_multiple\": 17.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 160.0, \"prob\": 0.3, \"notes\": \"Slower growth and multiple contraction due to economic headwinds.\"},\n \"base\": {\"target_price\": 175.0, \"prob\": 0.5, \"notes\": \"Steady execution with industry-average growth and stable multiples.\"},\n \"bull\": {\"target_price\": 190.0, \"prob\": 0.2, \"notes\": \"Accelerated adoption of digital health solutions driving outperformance.\"}\n },\n \"method_notes\": \"Valuation based on earnings growth and EV/EBITDA multiples. HOLD due to limited upside/downside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Research Model", "risks": [ "High leverage increasing financial vulnerability.", "Intense competition from other CROs and tech firms.", "Regulatory uncertainties in healthcare data usage.", "Macroeconomic downturns reducing pharmaceutical R&D." ], "ticker": "IQV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution with industry-average growth and stable multiples.", "target_price": 175 }, "bear": { "prob": 0.3, "notes": "Slower growth and multiple contraction due to economic headwinds.", "target_price": 160 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption of digital health solutions driving outperformance.", "target_price": 190 } }, "confidence": 0.65, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.065, "terminal_multiple": 17, "ebit_margin_target": 0.14 }, "key_drivers": [ { "driver": "Healthcare data demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Clinical trial outsourcing trend", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt servicing costs", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory changes in pharma", "impact": "MED", "direction": "NEG" }, { "driver": "Technological advancements in CRO", "impact": "MED", "direction": "POS" }, { "driver": "Economic cycles affecting R&D spend", "impact": "MED", "direction": "NEG" }, { "driver": "M&A activity in sector", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on earnings growth and EV/EBITDA multiples. HOLD due to limited upside/downside. Not investment advice.", "current_price": 172.54, "recommendation": "HOLD", "thesis_bullets": [ "Moderate revenue growth driven by healthcare digitization.", "Stable operating margins with potential efficiency gains.", "High debt levels pose financial risk.", "Industry competition may pressure pricing.", "Fair valuation at current multiples." ], "target_price_6m": 174, "target_price_12m": 175 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 344, "createdAt": "2026-04-09T05:21:09.210Z", "usage": { "inputTokens": 2204, "outputTokens": 4202, "costUsd": 0.002382 } }, { "id": "cmnr149jz04ghp658xq3ad0sb", "runId": "cmnr149jx04gep658uoroa2qz", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Analyst AI v1.2\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"IQV\",\n \"currency\": \"USD\",\n \"current_price\": 172.54,\n \"target_price_6m\": 188.0,\n \"target_price_12m\": 206.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Dominant global position in clinical research and healthcare data analytics segments.\",\n \"Valuation is attractive following a significant pull-back toward 52-week lows.\",\n \"Diversified revenue streams provide resilience against specific segment volatility.\",\n \"Anticipated recovery in small-to-mid cap biotech R&D funding cycles.\",\n \"Strong free cash flow generation supports ongoing debt deleveraging efforts.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biotech R&D Funding\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Clinical Trial Outsourcing Rates\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"AI-Driven Analytics Adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt Deleveraging Progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest Rate Environment\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Data Privacy Regulations\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"High leverage ratio increases sensitivity to interest rate fluctuations.\",\n \"Prolonged stagnation in early-stage biotech research spending.\",\n \"Intense competitive pricing pressure within the global CRO industry.\",\n \"Evolving global data privacy and protection legislative hurdles.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.075,\n \"ebit_margin_target\": 0.155,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 145.0,\n \"prob\": 0.2,\n \"notes\": \"Persistent funding headwinds and margin pressure from competitive pricing.\"\n },\n \"base\": {\n \"target_price\": 206.0,\n \"prob\": 0.6,\n \"notes\": \"Steady recovery in clinical trials and health analytics demand.\"\n },\n \"bull\": {\n \"target_price\": 240.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated AI adoption and a significant surge in biotech funding.\"\n }\n },\n \"method_notes\": \"Valuation based on 20x forward P/E and 16x EV/EBITDA. BUY recommendation reflects ~19% upside as biotech funding stabilizes, tempered by high leverage and macro uncertainty. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "Equity Research Analyst AI v1.2", "risks": [ "High leverage ratio increases sensitivity to interest rate fluctuations.", "Prolonged stagnation in early-stage biotech research spending.", "Intense competitive pricing pressure within the global CRO industry.", "Evolving global data privacy and protection legislative hurdles." ], "ticker": "IQV", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady recovery in clinical trials and health analytics demand.", "target_price": 206 }, "bear": { "prob": 0.2, "notes": "Persistent funding headwinds and margin pressure from competitive pricing.", "target_price": 145 }, "bull": { "prob": 0.2, "notes": "Accelerated AI adoption and a significant surge in biotech funding.", "target_price": 240 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.075, "terminal_multiple": 16, "ebit_margin_target": 0.155 }, "key_drivers": [ { "driver": "Biotech R&D Funding", "impact": "HIGH", "direction": "POS" }, { "driver": "Clinical Trial Outsourcing Rates", "impact": "MED", "direction": "POS" }, { "driver": "AI-Driven Analytics Adoption", "impact": "MED", "direction": "POS" }, { "driver": "Debt Deleveraging Progress", "impact": "MED", "direction": "POS" }, { "driver": "Interest Rate Environment", "impact": "HIGH", "direction": "NEG" }, { "driver": "Data Privacy Regulations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on 20x forward P/E and 16x EV/EBITDA. BUY recommendation reflects ~19% upside as biotech funding stabilizes, tempered by high leverage and macro uncertainty. Not investment advice.", "current_price": 172.54, "recommendation": "BUY", "thesis_bullets": [ "Dominant global position in clinical research and healthcare data analytics segments.", "Valuation is attractive following a significant pull-back toward 52-week lows.", "Diversified revenue streams provide resilience against specific segment volatility.", "Anticipated recovery in small-to-mid cap biotech R&D funding cycles.", "Strong free cash flow generation supports ongoing debt deleveraging efforts." ], "target_price_6m": 188, "target_price_12m": 206 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 27420, "createdAt": "2026-04-09T05:21:09.210Z", "usage": { "inputTokens": 2572, "outputTokens": 799, "costUsd": 0.014732 } }, { "id": "cmnr149jz04gfp658uive6e9w", "runId": "cmnr149jx04gep658uoroa2qz", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"GPT-5 Equity Research Model\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"IQV\",\"currency\":\"USD\",\"current_price\":172.54,\"target_price_6m\":182.0,\"target_price_12m\":190.0,\"recommendation\":\"BUY\",\"confidence\":0.63,\"thesis_bullets\":[\"Large, sticky healthcare data and CRO platform supports resilient demand.\",\"Backlog and clinical outsourcing trends can sustain mid-single-digit revenue growth.\",\"Forward P/E below prior peaks offers modest rerating potential.\",\"High leverage and weak liquidity limit flexibility and cap upside.\",\"Biotech funding softness and pricing pressure keep near-term growth mixed.\"],\"key_drivers\":[{\"driver\":\"R&D outsourcing demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Tech & Analytics renewal rates\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Book-to-bill and backlog conversion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin improvement from mix and productivity\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction and interest expense\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Biotech funding environment\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Large pharma spending discipline\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"FX and international exposure\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Clinical trial cancellations or slower starts\",\"Persistent biotech funding weakness\",\"Pricing pressure in data and analytics\",\"Higher rates prolong deleveraging\",\"Regulatory or data privacy constraints\"],\"assumptions\":{\"revenue_cagr_3y\":6.5,\"ebit_margin_target\":14.8,\"wacc\":8.8,\"terminal_multiple\":15.0},\"scenarios\":{\"bear\":{\"target_price\":150.0,\"prob\":0.25,\"notes\":\"Slower trial starts and limited margin gains keep valuation compressed.\"},\"base\":{\"target_price\":190.0,\"prob\":0.5,\"notes\":\"Mid-single-digit growth and modest deleveraging support a partial rerating.\"},\"bull\":{\"target_price\":220.0,\"prob\":0.25,\"notes\":\"Faster biotech recovery and stronger productivity lift earnings and multiples.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA using snapshot fundamentals and stated assumptions; 12M base implies ~10% upside, supporting BUY. Snapshot quote fields were not overridden; no sell-side targets used. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "GPT-5 Equity Research Model", "risks": [ "Clinical trial cancellations or slower starts", "Persistent biotech funding weakness", "Pricing pressure in data and analytics", "Higher rates prolong deleveraging", "Regulatory or data privacy constraints" ], "ticker": "IQV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Mid-single-digit growth and modest deleveraging support a partial rerating.", "target_price": 190 }, "bear": { "prob": 0.25, "notes": "Slower trial starts and limited margin gains keep valuation compressed.", "target_price": 150 }, "bull": { "prob": 0.25, "notes": "Faster biotech recovery and stronger productivity lift earnings and multiples.", "target_price": 220 } }, "confidence": 0.63, "assumptions": { "wacc": 8.8, "revenue_cagr_3y": 6.5, "terminal_multiple": 15, "ebit_margin_target": 14.8 }, "key_drivers": [ { "driver": "R&D outsourcing demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Tech & Analytics renewal rates", "impact": "MED", "direction": "POS" }, { "driver": "Book-to-bill and backlog conversion", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin improvement from mix and productivity", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction and interest expense", "impact": "MED", "direction": "POS" }, { "driver": "Biotech funding environment", "impact": "HIGH", "direction": "NEG" }, { "driver": "Large pharma spending discipline", "impact": "MED", "direction": "NEG" }, { "driver": "FX and international exposure", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended forward P/E and EV/EBITDA using snapshot fundamentals and stated assumptions; 12M base implies ~10% upside, supporting BUY. Snapshot quote fields were not overridden; no sell-side targets used. not investment advice", "current_price": 172.54, "recommendation": "BUY", "thesis_bullets": [ "Large, sticky healthcare data and CRO platform supports resilient demand.", "Backlog and clinical outsourcing trends can sustain mid-single-digit revenue growth.", "Forward P/E below prior peaks offers modest rerating potential.", "High leverage and weak liquidity limit flexibility and cap upside.", "Biotech funding softness and pricing pressure keep near-term growth mixed." ], "target_price_6m": 182, "target_price_12m": 190 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0f7f41e510f8be9c0069d75a2b8b0c81979ad459bddfe9faac", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 31819, "createdAt": "2026-04-09T05:21:09.210Z", "usage": { "inputTokens": 2477, "outputTokens": 1972, "costUsd": 0.031943 } }, { "id": "cmnr149jz04gip658fduutz3g", "runId": "cmnr149jx04gep658uoroa2qz", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"IQV\",\n \"currency\": \"USD\",\n \"current_price\": 172.54,\n \"target_price_6m\": 182,\n \"target_price_12m\": 195,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Dominant CRO with vast real-world patient data moat\",\n \"Mid-single digit revenue growth from R&D outsourcing\",\n \"Tech analytics segment drives higher long-term margins\",\n \"Elevated debt load increases interest expense pressure\",\n \"19.5x forward P/E appears reasonable vs growth outlook\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pharma R&D outsourcing demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"AI adoption in clinical trials\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Healthcare data analytics growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High debt servicing costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competition in CRO market\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory data privacy rules\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Emerging market expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Pharma client consolidation\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"High leverage and refinancing risk\",\n \"Slower than expected R&D spending\",\n \"Data privacy and regulatory hurdles\",\n \"Margin pressure from competition\",\n \"Economic downturn hitting clients\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.16,\n \"wacc\": 0.09,\n \"terminal_multiple\": 17\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 145,\n \"prob\": 0.25,\n \"notes\": \"Growth slowdown and multiple contraction from competition.\"\n },\n \"base\": {\n \"target_price\": 195,\n \"prob\": 0.5,\n \"notes\": \"Steady execution on targets with stable valuation.\"\n },\n \"bull\": {\n \"target_price\": 235,\n \"prob\": 0.25,\n \"notes\": \"AI efficiencies drive market share and margin upside.\"\n }\n },\n \"method_notes\": \"DCF using 6.5% rev CAGR, 16% EBIT margin, 9% WACC and 17x terminal. 13% upside to base case supports BUY despite debt and growth risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Model Recommendation", "risks": [ "High leverage and refinancing risk", "Slower than expected R&D spending", "Data privacy and regulatory hurdles", "Margin pressure from competition", "Economic downturn hitting clients" ], "ticker": "IQV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on targets with stable valuation.", "target_price": 195 }, "bear": { "prob": 0.25, "notes": "Growth slowdown and multiple contraction from competition.", "target_price": 145 }, "bull": { "prob": 0.25, "notes": "AI efficiencies drive market share and margin upside.", "target_price": 235 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.065, "terminal_multiple": 17, "ebit_margin_target": 0.16 }, "key_drivers": [ { "driver": "Pharma R&D outsourcing demand", "impact": "HIGH", "direction": "POS" }, { "driver": "AI adoption in clinical trials", "impact": "HIGH", "direction": "POS" }, { "driver": "Healthcare data analytics growth", "impact": "HIGH", "direction": "POS" }, { "driver": "High debt servicing costs", "impact": "MED", "direction": "NEG" }, { "driver": "Competition in CRO market", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory data privacy rules", "impact": "MED", "direction": "NEG" }, { "driver": "Emerging market expansion", "impact": "MED", "direction": "POS" }, { "driver": "Pharma client consolidation", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using 6.5% rev CAGR, 16% EBIT margin, 9% WACC and 17x terminal. 13% upside to base case supports BUY despite debt and growth risks. Not investment advice.", "current_price": 172.54, "recommendation": "BUY", "thesis_bullets": [ "Dominant CRO with vast real-world patient data moat", "Mid-single digit revenue growth from R&D outsourcing", "Tech analytics segment drives higher long-term margins", "Elevated debt load increases interest expense pressure", "19.5x forward P/E appears reasonable vs growth outlook" ], "target_price_6m": 182, "target_price_12m": 195 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "465ab09e-497d-94e6-9b31-d4ab64d7721a", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 13192, "createdAt": "2026-04-09T05:21:09.210Z", "usage": { "inputTokens": 2813, "outputTokens": 2606, "costUsd": 0.047529 } } ] } }